Skip to main content
Medical information Clinical review pending

Genetic Testing

FCGR2B Gene Malaria Resistance to Genetic Test

Understand your genetic predisposition to malaria resistance with the FCGR2B Gene Malaria Resistance Test. This genetic evaluation uses Next-Generation Sequencing (NGS) to analyze variations in the FCGR2B gene, providing insights for individuals in malaria-endemic areas or with a family history.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), Extracted DNA, or One drop of blood on FTA card.
Results
Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
A clinical history assessment and genetic counseling session are recommended before the test. A pedigree chart of family members affected by malaria may be helpful.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the FCGR2B Gene Malaria Resistance to Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals living in malaria-endemic regions.
  • ✓Individuals with a family history of malaria.
  • ✓Individuals planning travel to malaria-endemic areas.
  • ✓Patients seeking to understand genetic risk factors for malaria.
02

In plain language

What this test helps you understand

Identifies genetic variations in the FCGR2B gene associated with malaria resistance. Provides insights into individual susceptibility to malaria, potentially informing preventive measures.
The FCGR2B Gene Malaria Resistance Test is a specialized genetic evaluation designed to assess an individual's genetic predisposition related to malaria resistance. This test is particularly relevant for individuals living in or traveling to malaria-endemic regions, or those with a family history of the disease.

Utilizing advanced Next-Generation Sequencing (NGS) technology, this test provides a comprehensive analysis of genetic variations within the FCGR2B gene. This gene plays a role in the immune response to malaria, and understanding its variations can offer valuable insights into individual susceptibility and potential resistance.

This test is recommended for individuals seeking to understand their genetic risk factors related to malaria. Consulting with a healthcare provider is essential to interpret the results and discuss their implications for personal health management and preventive strategies.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history assessment and genetic counseling session are recommended before the test. A pedigree chart of family members affected by malaria may be helpful.
SampleBlood sample (EDTA tube), Extracted DNA, or One drop of blood on FTA card.
MethodologyNext-Generation Sequencing (NGS) is used to analyze genetic variations in the FCGR2B gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific variations in the FCGR2B gene. It does not assess all genetic factors related to malaria susceptibility. Results should be interpreted alongside clinical information.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The FCGR2B gene provides instructions for making a protein involved in the immune system's response to infections, including malaria.
This test is suitable for individuals living in or traveling to malaria-endemic areas, and those with a family history of malaria.
The results indicate the presence or absence of specific genetic variations in the FCGR2B gene associated with malaria resistance. Discuss the results with your doctor.
A sample can be collected as a blood draw, extracted DNA, or a single drop of blood on an FTA card.
Results are typically available within 3 to 4 weeks. Confirm the current turnaround time with the laboratory.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp